Search
Canagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalIt was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type … Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise
Categories: Drugs Used in DiabetesHetacillin
go.drugbank.com/drugs/DB00739ApprovedVet approvedWithdrawnHetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. … Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.
Golodirsen
go.drugbank.com/drugs/DB15593ApprovedInvestigational[L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of … This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12.
Categories: Compounds used in a research, industrial, or household settingFaricimab
go.drugbank.com/drugs/DB15303ApprovedInvestigational[A225985, A225990, A225995, A226000, A226005, A226010] Faricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc. … However, another set of factors, the Tie/Ang axis, comprising the transmembrane Tie-2 receptor and its soluble ligands Ang-1 and Ang-2, has been shown to play critical roles in mediating VEGF-A-induced
Treosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigational[L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575]
Caplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]
Delafloxacin
go.drugbank.com/drugs/DB11943ApprovedInvestigationalIt was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections. … Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections,
Oxilofrine
go.drugbank.com/drugs/DB11610ApprovedOxilofrine is used in combination with [DB11609] as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.
Plicamycin
go.drugbank.com/drugs/DB06810ApprovedWithdrawnIt has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. … Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus.
Categories: Compounds used in a research, industrial, or household settingZomepirac
go.drugbank.com/drugs/DB04828ApprovedWithdrawnZomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions. … The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.